NPC

NEW in @Health_Affairs: NPC & @TuftsCEVR captures how commercial plans often take 6+ months to update coverage after FDA label revisions and move faster to restrict access than expand it. Timeliness matters for patient access. Read the study: academic.oup.com/healthaffairss…

Some policy proposals view lowering prices and expanding access to treatments as a zero-sum game. But America can do both at the same time and build on decades of cancer-fighting progress. Read the full perspective here: cancerletter.com/guest-editoria… (4/4)

CMS and policymakers can still change course. By recognizing the value of innovative treatments, supporting combination therapies, and negotiating treatments with care, we can ensure those counting on innovative treatments receive them. (3/4)

America is winning the war on cancer, but recent policies such as the Inflation Reduction Act are putting 55 years of progress at risk. As @drjmob writes in @TheCancerLetter, we can protect affordability without stalling innovation 🧵(1/4)

John O'Brien (@npcnow): "The treatments we now have would have been science fiction when I was in pharmacy school. The sustained, high-risk investments from scientists at drug companies have yielded remarkable innovations." cancerletter.com/guest-editoria…

In a new @AJMC_Journal article, my @npcnow colleagues and I explore what American patients value and whether foreign health technology assessment (HTA) bodies incorporate American patients’ values. Read more here: ajmc.com/view/contribut…

Read more in @AJMC_Journal at: ajmc.com/view/contribut…

A new article in @AJMC_Journal explores what American patients value and whether foreign health technology assessment (#HTA) bodies incorporate American patients’ values. It looks at two key dimensions: patient access and autonomy, and the breadth of treatment impacts considered.

New research from the National Pharmaceutical Council (#NPC) supports consistent and equitable patient access to #genetherapies. Read more in @SpringerNature’s PharmacoEconomics at link.springer.com/article/10.100…

A new @amcporg JMCP commentary from NPC's Kimberly Westrich describes new regulatory requirements for patient engagement and outlines opportunities for the managed care community to expand the role of patients in healthcare decision-making.  📚Read it at jmcp.org/doi/10.18553/j…

Our SVP Stephanie Krenrich joined a great panel at AMCP Nexus today on 340B, with @ashpofficial's Jillanne Schulte Wall, @npcnow's Kimberly Westrich, and @umdlaw's Bill Sarraille. Thanks @amcporg for highlighting this critical healthcare policy for community health centers!

🔥 𝐃𝐂𝐋𝐅2026 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐂𝐫𝐨𝐬𝐬𝐟𝐢𝐫𝐞 — 𝐓𝐡𝐞 340𝐁 𝐃𝐫𝐮𝐠 𝐏𝐫𝐢𝐜𝐢𝐧𝐠 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 🔥 The #340B program is one of the most consequential issues in healthcare today. At the 𝐃𝐫𝐮𝐠 𝐂𝐡𝐚𝐧𝐧𝐞𝐥𝐬 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐅𝐨𝐫𝐮𝐦 2026, two of the industry’s most influential voices will go head-to-head: ✅ Maureen Testoni, JD, President & CEO, @340BHealth ✅ John O'Brien, PharmD, MPH, President & CEO, National Pharmaceutical Council @npcnow Moderated by: 🎙️Luke Greenwalt, MBA, Vice President and Lead, @IQVIA_US Market Access Center of Excellence This session promises a candid, high-stakes exchange you won’t want to miss! 🎟️ Request an Invite: drugch.nl/DCLF #DCLF2026 #DrugPricing #HealthPolicy

A new @Health_Affairs Scholar commentary explores the unique perspectives of health technology investors and health technology assessment #HTA bodies in the biopharmaceutical innovation ecosystem. academic.oup.com/healthaffairss… @drjmob @mel_whittington @ProfLouGarrison @Campbell_JonD

Kimberly Westrich, MA, chief strategy officer at @npcnow, told #AJMC at #AMCP2025 about the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and #Medicaid committees. Watch here: bit.ly/3FUTQ1O

💡All but one reported they were more likely to consider a larger launch indication for products they invest in & may wait longer to enter clinical development to have a better chance of success with a larger indication rather than starting sooner with a smaller indication. (5/5)

💡More than three quarters (77%) of investors shared that the IRA’s “#pillpenalty” has created a disincentive to investing in small molecules (4/5)

Investors across a range of stages, investment sizes, and fund types frequently reported that the #IRA of 2022 is exacerbating challenges in bringing innovative new medicines to market, according to new research in @Health_Affairs at academic.oup.com/healthaffairss… 🧵